Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide

  • López-Valero, Israel
  • Saiz-Ladera, Cristina
  • Torres, Sofía
  • Hernández-Tiedra, Sonia
  • García-Taboada, Elena
  • Rodríguez-Fornés, Fátima
  • Barba, Marina
  • Dávila, David
  • Salvador-Tormo, Nélida
  • Guzmán, Manuel
  • Sepúlveda, Juan M
  • Sánchez-Gómez, Pilar
  • Lorente, Mar
  • Velasco, Guillermo
Glioblastoma multiforme (GBM) is the most frequent and aggressive type of brain tumor due, at least in part, to its poor response to current anticancer treatments. These features could be explained, at least partially, by the presence within the tumor mass of a small population of cells termed Glioma Initiating Cells (GICs) that has been proposed to be responsible for the relapses occurring in this disease. Thus, the development of novel therapeutic approaches (and specifically those targeting the population of GICs) is urgently needed to improve the survival of the patients suffering this devastating disease. Previous observations by our group and others have shown that Δ9-Tetrahydrocannabinol (THC, the main active ingredient of marijuana) and other cannabinoids including cannabidiol (CBD) exert antitumoral actions in several animal models of cancer, including gliomas. We also found that the administration of THC (or of THC + CBD at a 1:1 ratio) in combination with temozolomide (TMZ), the benchmark agent for the treatment of GBM, synergistically reduces the growth of glioma xenografts. In this work we investigated the effect of the combination of TMZ and THC:CBD mixtures containing different ratios of the two cannabinoids in preclinical glioma models, including those derived from GICs. Our findings show that TMZ + THC:CBD combinations containing a higher proportion of CDB (but not TMZ + CBD alone) produce a similar antitumoral effect as the administration of TMZ together with THC and CBD at a 1:1 ratio in xenografts generated with glioma cell lines. In addition, we also found that the administration of TMZ + THC:CBD at a 1:1 ratio reduced the growth of orthotopic xenografts generated with GICs derived from GBM patients and enhanced the survival of the animals bearing these intracranial xenografts. Remarkably, the antitumoral effect observed in GICs-derived xenografts was stronger when TMZ was administered together with cannabinoid combinations containing a higher proportion of CBD. These findings support the notion that the administration of TMZ together with THC:CBD combinations - and specifically those containing a higher proportion of CBD - may be therapeutically explored to target the population of GICs in GBM.
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells

  • Morell, María Cecilia
  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Vara Ciruelos, Diana|||0000-0002-9508-2648
  • Ramos Torres, Ágata
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate cancer. The aim of this study was to determine the influence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells. METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6, for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small interfering RNA. RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers neuron-specific enolase and ?III tubulin (?III Tub). Treatment with 3??M WIN inhibited NK differentiation of LNCaP cells. The cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2 dramatically decreases. CONCLUSIONS: Taken together, we demonstrate that PI3K/Akt/AMPK might be an important axis modulating NE differentiation of prostate cancer that is blocked by the cannabinoid WIN, pointing to a therapeutic potential of cannabinoids against NE prostate cancer., Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Fundación Tatiana Pérez de Guzmán el Bueno, Fondo Europeo de Desarrollo Regional, Comunidad de Madrid
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Quesada Sánchez, Sergio
  • Ramos Torres, Ágata
  • Gargantilla López, Marta
  • Priego, Eva Maria
  • Raynal, Sophie
  • Lepifre, Franck
  • Gasalla Herráiz, José Manuel
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Castro Morera, Ana
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of ?1 or ?2 isoforms as well as in vitro assays using human recombinant ?1?1?1 or ?2?1?1 AMPK isoforms revealed that compound 8c exhibit preference for AMPK?1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer., Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Fondo Europeo de Desarrollo Regional, Comunidad Autónoma de Madrid, Fundación Tatiana Pérez de Guzmán el Bueno, Junta para la Ampliacion de Estudios
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells

  • Ramos Torres, Ágata
  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Morell, María Cecilia
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
Capsaicin, the pungent ingredient of red hot chili peepers, has been shown to have anti-cancer activities in several cancer cells, including prostate cancer. Several molecular mechanisms have been proposed on its chemopreventive action, including ceramide accumulation, endoplasmic reticulum stress induction and NF?B inhibition. However, the precise mechanisms by which capsaicin exerts its anti-proliferative effect in prostate cancer cells remain questionable. Herein, we have tested the involvement of autophagy on the capsaicin mechanism of action on prostate cancer LNCaP and PC-3 cells. The results showed that capsaicin induced prostate cancer cell death in a time- and concentration-dependent manner, increased the levels of microtubule-associated protein light chain 3-II (LC3-II, a marker of autophagy) and the accumulation of the cargo protein p62 suggesting an autophagy blockage. Moreover, confocal microscopy revealed that capsaicin treatment increased lysosomes which co-localized with LC3 positive vesicles in a similar extent to that produced by the lysosomal protease inhibitors E64 and pepstatin pointing to an autophagolysosomes breakdown inhibition. Furthermore, we found that capsaicin triggered ROS generation in cells, while the levels of ROS decreased with N-acetyl-cysteine (NAC), a ROS scavenger. Co-treatment of cells with NAC and capsaicin abrogated the effects of capsaicin on autophagy and cell death. Normal prostate PNT2 and RWPE-1 cells were more resistant to capsaicin-induced cytotoxicity and did not accumulate p62 protein. Taken together, these results suggest that ROS-mediated capsaicin-induced autophagy blockage contributes to antiproliferation in prostate cancer cells, which provides new insights into the anticancer molecular mechanism of capsaicin., Ministerio de Economía y Competitividad, Comunidad Autónoma de Madrid, Fundación TPG, Junta de Comunidades de Castilla-La Mancha